Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Tumor Vaccine + Nivolumab in Follicular Lymphoma
NCT03121677Phase 1Terminated
- Sponsor
- Washington University School of Medicine
- Start
- Oct 2018
- Primary completion
- Sep 2020
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in follicular lymphoma (FL), sponsored by Washington University School of Medicine. Primary endpoint: Feasibility and safety of vaccine in combination with nivolumab at 6 months. Started Oct 2018; status: terminated.
02
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT03121677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03121677.